Adult ADHD is having a moment: patients are showing up with TikTok checklists, AI-generated “diagnoses,” and a lot of lived frustration. And honestly, that makes sense: untreated ADHD can look like chronic overwhelm, missed deadlines, “brain fog,” relationship conflict, and repeated experiences of feeling like you should be able to do things you can’t consistently execute. In primary care, the challenge is sorting out what’s ADHD, what’s a mimic (or comorbidity), and how to treat safely and effectively.
Adult ADHD isn’t just “can’t pay attention.” It often shows up as executive dysfunction: difficulty staying focused on tasks (especially boring ones), organizing, prioritizing, following through, managing time, and remembering details. Many patients can hyperfocus on things they enjoy, which can confuse clinicians (and families) into thinking “this can’t be ADHD.”
A classic story: someone who was a high-functioning student built scaffolding (structure, deadlines, supportive environments), then life got bigger — new job demands, parenting, remote work — and the scaffolding collapsed. They present with anxiety, burnout, or depression, but the root driver may be longstanding ADHD.
Adult ADHD is under-recognized, especially in women and people of color, because symptoms may be more internalized (restlessness, emotional dysregulation, chronic overwhelm) and because diagnostic pathways aren’t equitable. Children from minoritized racial and ethnic backgrounds are less likely to be diagnosed with ADHD, more likely to be labeled with conduct disorder, and less likely to receive medication, creating downstream consequences that can follow them into adulthood.
A key point: current thinking does not support ADHD developing “out of nowhere” in adulthood. Many adults were simply missed earlier and only present when demands exceeded coping strategies.
Here’s a PCP-friendly approach:
1. Screen efficiently
Use the ASRS v1.1 (6-item) screener — quick, validated, and free.
Consider the DIVA-5 when you need a more structured diagnostic interview.
2. Confirm the “ADHD pattern”
Onset before age 12, lifelong pattern, and symptoms across settings (work/home/social).
Look for functional impairment in at least two domains and rule out common mimics: sleep deprivation, anxiety, depression, trauma, and substance use.
3. Neuropsych testing: not for everyone
The diagnosis is clinical; a strong interview + collateral history often beats testing.
Neuropsych can help when collateral is lacking or comorbidities/confounders muddy the picture.
CBT for ADHD (CBT-ADHD) and skills-based executive function work have the best non-pharmacologic evidence, especially helpful when anxiety/depression co-occur. Coaching, time-blocking, mindfulness-based strategies, and practical tools/apps can meaningfully improve function.
Medication: for most adults, stimulants are first-line unless contraindicated. Start with an extended-release methylphenidate or amphetamine, titrate slowly, and monitor. Non-stimulants like atomoxetine, bupropion (off-label), or viloxazine can be strong options when misuse risk is higher, or stimulants aren’t tolerated.
Comorbidities matter
SUD: consider atomoxetine/bupropion/viloxazine; if stimulants are used, use guardrails.
Anxiety: SSRI/SNRI + stimulant can be appropriate.
Bipolar: mood stabilizer first, then consider stimulant.
Side effects & contraindications
Counsel about insomnia, headache, appetite/weight effects, BP/HR increases, dry mouth, and possible worsening anxiety/mood symptoms. Avoid stimulants in uncontrolled hypertension, angina, prior MI, arrhythmias, significant valve disease, or cardiomyopathy; get CV history and consider EKG if history/symptoms warrant it.
If there’s a history of substance use disorder, assess stability. Extended-release stimulants may still be appropriate with PDMP checks, pill counts, smaller quantities, and integrated behavioral health; use non-stimulants if there’s active substance use.
Also: misuse is real. In a large US study, 25.3% of adults using prescription stimulants reported misuse, and 9.0% met criteria for prescription stimulant use disorder; misuse and PSUD were higher with amphetamines than methylphenidate, so screen thoughtfully for stimulant use disorder.
Plan an early follow-up (often ~1 month) to review symptoms, side effects, and overall mental health, then adjust. Consider a short-acting “booster” dose for specific late-day needs (homework, chores, social events) rather than adding a second long-acting dose.
If a patient transfers in already on stimulants: confirm diagnosis via records/collateral, check PDMP, assess benefit/harms, and set clear refill expectations — avoid abrupt discontinuation unless safety requires it.
For more, listen to our Primary Care Reviews and Perspectives podcast, "Focus, Please: Adult ADHD," or subscribe to Primary Care RAP to listen.